-
公开(公告)号：US07592017B2
公开(公告)日：2009-09-22
申请号：US10631980
申请日：2003-07-31
CPC分类号： A61L31/06 , A61F2/0063 , A61F2210/0004 , A61K31/765 , A61L31/148 , C08L67/04
摘要： Resorbable lactide polymer thin membranes are disclosed. The thin membranes are constructed of polylactide resorbable polymers, which are engineered to be absorbed into the body relatively slowly over time in order to reduce potential negative side effects. The membranes are formed to have very thin thicknesses, for example, thicknesses between about 0.010 mm and about 0.300 mm. The membranes can be extruded from polylactide polymers having a relatively high viscosity property, can be preshaped with relatively thick portions, and can be stored in sterile packages.
摘要翻译： 公开了可再吸收的丙交酯聚合物薄膜。 薄膜由聚丙交酯可吸收聚合物构成，其被设计成随时间相对缓慢地吸收到身体中以减少潜在的负面副作用。 膜形成为具有非常薄的厚度，例如厚度在约0.010mm和约0.300mm之间。 膜可以从具有相对高粘度性质的聚丙交酯聚合物挤出，可以用相对较厚的部分预成型，并且可以储存在无菌包装中。
-
公开(公告)号：US5609866A
公开(公告)日：1997-03-11
申请号：US163609
申请日：1993-12-06
申请人： Mohammed A. Khan , John F. Moellmer
发明人： Mohammed A. Khan , John F. Moellmer
CPC分类号： A61K9/0014 , A61K31/79 , A61K33/18 , A61K47/10 , A61K47/48176
摘要： Sterilized povidone-iodine (polyvinylpyrrolidone-iodine) in an ointment form is obtained by preparation of a mixture of purified water, povidone-iodine, a non-ionic gelling agent, and a non-ionic low suds surfactant. The ointment is a liquid in the temperature range of about 2.degree. C. to 9.degree. C. because of the influence of the non-ionic gelling agent. At room temperature, the mixture forms a free standing ointment which can be sterilized by gamma radiation without degradation of its antimicrobial efficacy, viscosity or shelf life. The ointment is easily prepared by using chilled purified water which maintains the mixture as a liquid while all of the ingredients are mixed together. At room temperature the mixture becomes a free standing ointment.
摘要翻译： 通过制备纯化水，聚维酮碘，非离子胶凝剂和非离子低泡表面活性剂的混合物，得到软膏形式的灭活聚维酮碘（聚乙烯吡咯烷酮 - 碘）。 由于非离子胶凝剂的影响，软膏是在约2℃至9℃的温度范围内的液体。 在室温下，混合物形成自立式软膏，其可以通过γ辐射灭菌而不降低其抗菌效力，粘度或保质期。 通过使用冷冻纯化水容易地制备软膏，其将混合物保持为液体，同时将所有成分混合在一起。 在室温下，混合物成为独立软膏。
-
3.发明授权
公开(公告)号：US5849588A
公开(公告)日：1998-12-15
申请号：US690955
申请日：1996-08-01
IPC分类号： A61B10/00 , A61B10/02 , A61B19/00 , A61K35/12 , A61K35/28 , A61L27/38 , A61L27/60 , C12N5/00 , C12N5/071 , C12N5/077 , C12N5/0789 , C12M3/00 , A61K2/00
CPC分类号： C12N5/0671 , A61B90/00 , A61K35/28 , A61L27/3604 , A61L27/3629 , A61L27/3637 , A61L27/3641 , A61L27/3804 , A61L27/3839 , A61L27/3886 , A61L27/3895 , A61L27/60 , A61B2010/0258 , A61K2035/124 , A61K35/12 , C12N2500/34 , C12N2501/11 , C12N2501/33 , C12N2501/335 , C12N2501/39 , C12N2502/13 , C12N2503/04 , C12N2510/00 , C12N2533/30 , C12N2533/40 , C12N2533/70
摘要： The present invention relates to a three-dimensional cell and tissue culture system. In particular, it relates to this culture system for the long term culture of liver cells and tissues in vitro in an environment that more closely approximates that found in vivo. The culture system described herein provides for proliferation and appropriate liver cell maturation to form structures analogous to tissue counterparts in vivo. The resulting liver tissues survive for prolonged periods, perform liver-specific functions, and maintain hepatic tissue architecture following in vivo implantation. The liver cultures have a variety of applications ranging from transplantation or implantation in vivo, to screening cytotoxic compounds and pharmaceutical compounds in vitro, to the production of biologically active molecules in "bioreactors" and to the construction of extracorporeal liver assist device.
摘要翻译： 本发明涉及三维细胞和组织培养系统。 特别地，它涉及这种用于在与体内发现更接近的环境中长期培养肝细胞和组织的培养体系。 本文描述的培养系统提供增殖和合适的肝细胞成熟以形成类似于体内组织对应物的结构。 所得肝组织长时间存活，进行肝特异性功能，并在体内植入后维持肝组织结构。 肝脏培养物具有多种应用，从体内移植或植入到体外筛选细胞毒性化合物和药物化合物，在“生物反应器”中生产生物活性分子以及体外肝辅助装置的构建。
-
公开(公告)号：US5712252A
公开(公告)日：1998-01-27
申请号：US611613
申请日：1996-03-08
申请人： Dean Preston Smith
发明人： Dean Preston Smith
CPC分类号： A61K38/1709
摘要： The present invention relates to a method of augmenting soft tissue in a mammal which includes injecting keratin into the soft tissue. The method of the present invention may be used to treat incontinence and vesicoureteral reflux.
摘要翻译： 本发明涉及一种增加哺乳动物软组织的方法，包括将角蛋白注入软组织。 本发明的方法可用于治疗失禁和膀胱输尿管反流。
-
5.发明授权Methods for stabilizing ingredients within cosmetics, personal care and household products 有权在化妆品，个人护理和家庭用品中稳定成分的方法公开(公告)号：US07150876B2
公开(公告)日：2006-12-19
申请号：US11115395
申请日：2005-04-27
IPC分类号： A61K2/00
CPC分类号： A61K8/37 , A61K8/42 , A61K2800/52 , A61Q1/04 , A61Q1/06 , A61Q3/02 , A61Q5/02 , A61Q5/06 , A61Q5/065 , A61Q5/12 , A61Q11/00 , A61Q15/00 , A61Q17/02 , A61Q17/04 , A61Q19/00 , A61Q19/04 , A61Q19/10 , C11D3/0084 , C11D3/2093 , C11D3/26 , C11D3/32 , C11D3/40 , C11D3/50 , C11D7/266 , C11D7/3254 , C11D7/3263
摘要： The present invention relates to methods and compositions for using photostabilizer compounds for stabilizing formulation ingredients, like flavors, fragrances, colors, antioxidants, polymers, within cosmetics, personal care and household products, against degradation from sun light, heat and air oxidation resulting in improvement in storage stability, viscosity, and maintenance of color of the formulated products.
摘要翻译： 本发明涉及使用光稳定剂化合物来稳定制剂成分（如香料，香料，颜色，抗氧化剂，聚合物，化妆品，个人护理和家用产品）中的防晒剂，防止太阳光降解，导致改善的热和空气氧化的方法和组合物 在储存稳定性，粘度和维护配方产品的颜色。
-
公开(公告)号：US07112320B1
公开(公告)日：2006-09-26
申请号：US10049992
申请日：2000-08-21
申请人： Andre Beaulieu , Robert Paquin , Benoit Lariviere
发明人： Andre Beaulieu , Robert Paquin , Benoit Lariviere
摘要： A concentrated solution of a wound healing promoter, in particular fibronectin, is used to develop solid wound dressings. The solid wound dressings containing fibronectin are easy to apply, easy to remove, and deliver fibronectin in a range of physiologically active dosages.
摘要翻译： 使用伤口愈合促进剂，特别是纤连蛋白的浓缩溶液来开发固体伤口敷料。 含有纤粘连蛋白的固体伤口敷料易于施用，易于除去，并在一定范围的生理活性剂量中递送纤连蛋白。
-
公开(公告)号：US07377943B2
公开(公告)日：2008-05-27
申请号：US10480918
申请日：2002-06-14
申请人： Wolf-Dieter Müller , Georg Berger
发明人： Wolf-Dieter Müller , Georg Berger
CPC分类号： C03C4/0021 , A61L27/306 , A61L27/32 , A61L27/425 , B24C1/06 , B24C11/00 , C03C4/0007 , C03C10/16
摘要： The invention relates to a metallic implant, which has vitreous-crystalline bioactive material on the surface thereof. According to the invention, a metallic implant base body arranged on the surface of the particles has a bioactive, vitreous-crystalline material consisting of 15-45 wt. % CaO, 40-45 wt. % P2O5, 10-40 wt. % ZrO2 and 0.7-3.5 wt. % fluoride, having apatite and calcium zirconium phosphate as main crystalline and a glass phase as an auxiliary component. Said vitreous crystalline material contains at least 35 wt. % main crystal phases and at least 5-15 wt. % auxiliary compounds. All of the percentage data is expressed in relation to the total weight of the vitreous crystalline material and the particle size of the vitreous crystalline material is between 60-350 μm.
摘要翻译： 本发明涉及一种在其表面上具有玻璃态生物活性物质的金属植入物。 根据本发明，布置在颗粒表面上的金属植入物基体具有生物活性的玻璃状结晶材料，其由15-45wt。 ％CaO，40-45wt。 ％P 2 O 5，10-40重量％ ％ZrO 2和0.7-3.5wt。 ％氟化物，磷灰石和磷酸钙锆为主晶，玻璃相为辅助成分。 所述玻璃态结晶材料含有至少35wt。 ％主晶相和至少5-15wt。 ％辅助化合物。 所有百分比数据都以玻璃态结晶材料的总重量表示，玻璃状结晶材料的粒径在60-350μm之间。
-
公开(公告)号：US06849262B2
公开(公告)日：2005-02-01
申请号：US10067331
申请日：2002-02-07
申请人： Jeremy Ollerenshaw , Umit Yuksel , Kirby S. Black
发明人： Jeremy Ollerenshaw , Umit Yuksel , Kirby S. Black
IPC分类号： A61K45/00 , A61K31/11 , A61K38/00 , A61L27/34 , A61L27/36 , A61L31/00 , A61L31/10 , A61P9/14 , A61K9/00 , A61K35/34 , A61K2/00 , A61K2/06
CPC分类号： A61L31/10 , A61L27/34 , A61L27/3625 , A61L27/3683 , A61L31/005 , Y10S623/92 , Y10S623/921 , C08L89/06
摘要： This invention relates to methods of coating the lumenal surface of a blood vessel, or other tissue cavity, and to compositions suitable for use in same.
摘要翻译： 本发明涉及涂覆血管或其他组织腔的腔表面的方法以及适用于其的组合物。
-
公开(公告)号：US08353399B2
公开(公告)日：2013-01-15
申请号：US13282568
申请日：2011-10-27
CPC分类号： A61K8/042 , A61K8/0212 , A61K8/676 , A61K8/73 , A61K2800/88 , A61Q19/00 , A61Q19/08
摘要： Disclosed is a preparation-at-use device comprising: (1) a pre-formed hydrogel component packaged in a first compartment; the pre-formed hydrogel component comprising a gelling agent and a solvent; and (2) a benefit component packaged in a second compartment; the benefit component comprising at least one compound that is unstable when contacted with the pre-formed hydrogel component; wherein the first and second compartments are separately packaged prior to use, and wherein the device comprises means for contacting the pre-formed hydrogel component and benefit component upon use.
摘要翻译： 公开了一种制备用途装置，包括：（1）预先形成的包封在第一隔室中的水凝胶组分; 预形成的水凝胶组分包含胶凝剂和溶剂; 和（2）包装在第二隔室中的益处组件; 所述有益成分包含至少一种当与预形成的水凝胶组分接触时不稳定的化合物; 其中所述第一和第二隔室在使用之前被分开包装，并且其中所述装置包括用于在使用时接触预先形成的水凝胶组分和有益成分的装置。
-
公开(公告)号：US06995236B2
公开(公告)日：2006-02-07
申请号：US10138634
申请日：2002-05-06
CPC分类号： G01N33/92 , C07K14/43536
摘要： An object of the present invention is to provide a protein useful as a sphingomyelin detecting probe, which specifically recognizes sphingomyelin and has low cytotoxicity. The present invention provides a protein which has an amino acid sequence having, as the amino acid sequence from the 1st to the 48th amino acid, the amino acid sequence from the 1st to the 48th amino acid in Lysenin 1, and as the amino acid sequence from the 49th to the 298th amino acid, the amino acid sequence from the 51st to the 300th amino acid in Lysenin 3; and a protein which is obtained by deleting N terminal and/or C terminal from earthworm toxins Lysenin 1 or 3, and which specifically recognizes sphingomyelin.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.012 秒)
